Sangamo Biosciences (SGMO) AI Stock Analysis

• Market Cap: $155.12M
• Dividend Yield: N/A
• Average Volume (3M): 6.92M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.97
• Revenue Growth: -37.13%
• EPS Growth: 40.47%
• Country: US
• Employees: 183
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.11
• Shares Outstanding: 336,494,480
• 10 Day Avg. Volume: 11,401,690
• 30 Day Avg. Volume: 6,920,350
• PEG Ratio: 0.03
• Price to Book (P/B): 9.04
• Price to Sales (P/S): 3.56
• P/FCF Ratio: -3.05
• Enterprise Value/Market Cap: 1.29
• Enterprise Value/Revenue: 6.08
• Enterprise Value/Gross Profit: 6.08
• Enterprise Value/Ebitda: -1.94
• 1Y Price Target: $4.33
• Price Target Upside: 841.30% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): -0.35
• Revenue Forecast (FY): $59.32M

• Rating: 45 Neutral
• Price Target: $0.50 ▲(8.70% Upside)

Sangamo Biosciences' overall stock score is primarily impacted by its poor financial performance and valuation metrics, which reflect significant operational and profitability challenges. Despite these issues, the positive developments in clinical trials and FDA endorsements provide some optimism, as highlighted in the earnings call. Technical indicators suggest bearish momentum, further weighing down the score.

Positive Factors

FDA Endorsement

The FDA's acceptance of a rolling submission for ST-920 indicates regulatory support, enhancing the potential for accelerated approval and market entry, which could significantly boost Sangamo's market position and revenue prospects in the gene therapy space.

Pipeline Advancement

Advancing the neurology pipeline with patient enrollment in the STAND study demonstrates Sangamo's commitment to expanding its therapeutic offerings, potentially leading to new revenue streams and strengthening its competitive position in the biotech industry.

Extended Cash Runway

An extended cash runway provides Sangamo with financial stability to continue its R&D activities and strategic initiatives without immediate pressure to secure additional funding, supporting long-term operational sustainability.

Negative Factors

Declining Revenue

A significant decline in revenue reflects challenges in monetizing its pipeline and partnerships, which could hinder Sangamo's ability to invest in future growth and maintain competitive advantages in the biotech industry.

Negative Cash Flow

Ongoing negative cash flow indicates difficulties in generating sufficient cash from operations, which may limit Sangamo's ability to fund R&D and strategic initiatives, impacting its long-term growth prospects.

Funding Challenges

The need for additional funding highlights financial vulnerabilities that could constrain Sangamo's ability to advance its pipeline and capitalize on market opportunities, potentially affecting its competitive position and growth trajectory.

Sangamo Biosciences Business Overview & Revenue Model

Company Description

Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucleases, which are proteins used in modifying DNA sequences by adding or knocking out specific genes; and ZFP transcription factors proteins used in increasing or decreasing gene expression. It develops SB-525, which is in Phase III AFFINE clinical trial for the treatment of hemophilia A; ST-920, a gene therapy, which is in Phase I/II STAAR clinical trials for the treatment of Fabry disease; and SAR445136, a cell therapy, which is in Phase I/II PRECIZN-1 clinical trials for the treatment of sickle cell disease. The company also develops TX200, chimeric antigen receptor for the treatment of HLA-A2 mismatched kidney transplant rejection; KITE-037, a cell therapy for the treatment of cancer; ST-501 for the treatment of tauopathies; and ST-502 for the treatment of synucleinopathies, including Parkinson's disease and neuromuscular disease. It has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Brisbane, California.

How the Company Makes Money

Sangamo generates revenue through a combination of collaborations, licensing agreements, and funding from governmental grants and private investments. Key revenue streams include milestone payments and royalties from partnerships with major pharmaceutical companies, such as Pfizer and Biogen, in which Sangamo provides its gene editing technology for the development of novel therapies. Additionally, the company may receive upfront payments in collaboration agreements, as well as potential future earnings tied to the successful commercialization of partnered products. Sangamo also engages in research grants and funding opportunities to support its R&D efforts, further contributing to its overall revenue.

Sangamo Biosciences Financial Statement Overview

Summary

Sangamo Biosciences is facing significant financial challenges, including declining revenue and profitability, a weakening balance sheet with increased leverage, and persistent negative cash flows. These factors collectively indicate financial instability and increased operational risks.

Income Statement

Sangamo Biosciences has shown significant volatility in its revenue and profitability metrics. There has been a substantial decline in total revenue from $176.23M in 2023 to $57.8M in 2024, representing a negative revenue growth trend. Gross profit margins have been inconsistent, and the company consistently reports negative EBIT and net income margins, indicating ongoing operational and profitability challenges.

Balance Sheet

The balance sheet reflects a strained financial position with a declining equity base, from $82.89M in 2023 to $22.77M in 2024. The debt-to-equity ratio has worsened due to reduced equity, suggesting increased leverage. The equity ratio declined significantly, indicating reduced shareholder equity relative to total assets, potentially increasing financial risk.

Cash Flow

The cash flow statements highlight persistent negative free cash flow, with a slight improvement from -$246M in 2023 to -$67.4M in 2024. Operating cash flow has remained negative, raising concerns about the company's ability to generate cash from operations. The free cash flow to net income ratio remains unfavorable, reflecting poor cash conversion.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	32.88M	57.80M	176.23M	111.30M	110.70M	118.19M
Gross Profit	32.88M	57.80M	176.23M	99.19M	110.70M	-62.45M
EBITDA	-102.81M	-89.09M	-96.80M	-189.17M	-165.70M	-123.87M
Net Income	-108.91M	-97.94M	-257.83M	-192.28M	-178.29M	-121.00M
Balance Sheet
Total Assets	88.64M	101.64M	165.32M	562.51M	721.92M	938.55M
Cash, Cash Equivalents and Short-Term Investments	30.53M	41.92M	81.00M	277.63M	376.55M	641.42M
Total Debt	25.42M	30.57M	38.10M	43.11M	48.08M	42.09M
Total Liabilities	82.40M	78.86M	82.43M	267.55M	346.58M	441.18M
Stockholders Equity	6.24M	22.77M	82.89M	294.96M	375.34M	498.23M
Cash Flow
Free Cash Flow	-76.40M	-67.41M	-246.00M	-243.80M	-256.53M	155.16M
Operating Cash Flow	-76.16M	-67.14M	-224.84M	-223.63M	-233.25M	169.88M
Investing Cash Flow	1.24M	37.52M	153.53M	59.28M	248.20M	-271.63M
Financing Cash Flow	62.94M	28.38M	14.59M	84.66M	32.86M	153.10M

Sangamo Biosciences Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.46
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SGMO, the sentiment is Negative. The current price of 0.46 is below the 20-day moving average (MA) of 0.47, below the 50-day MA of 0.57, and below the 200-day MA of 0.63, indicating a bearish trend. The MACD of -0.04 indicates Negative momentum. The RSI at 44.04 is Neutral, neither overbought nor oversold. The STOCH value of 36.65 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SGMO.

Sangamo Biosciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SGMO	45 Neutral	$155.12M	―	-480.02%	―	-37.13%	40.47%
APLT	39 Underperform	$37.27M	―	-680.47%	―	―	―
CABA	39 Underperform	$247.40M	―	-101.06%	―	―	-17.21%
CRBU	38 Underperform	$202.08M	-1.22	-74.28%	―	-19.00%	-2.72%
BDTX	33 Underperform	$217.64M	10.53	19.23%	―	―	―
ELTX	30 Underperform	$149.50M	-2.19	―	―	―	17.36%

Sangamo Biosciences Corporate Events

Sangamo Biosciences’ Positive Outlook in Latest Earnings Call

Sangamo Biosciences’ recent earnings call painted a picture of optimism, underscored by significant clinical advancements and a solid endorsement from the FDA. The company’s progress in Fabry disease and neurology programs, along with an extended cash runway, were highlighted as key positive developments. Despite some challenges in securing long-term funding and potential regulatory uncertainties, the overall sentiment was positive, with the highlights outweighing the lowlights.

Sangamo Therapeutics Reports Q3 2025 Financial Results

Sangamo Therapeutics is a genomic medicine company focused on developing treatments for serious neurological diseases through innovative technologies like zinc finger epigenetic regulators and proprietary capsid discovery platforms. The company recently reported its third-quarter 2025 financial results, highlighting significant progress in its clinical and pre-clinical pipeline, including advancements in Fabry disease and chronic neuropathic pain studies.

Sangamo Biosciences Granted Nasdaq Compliance Extension

On October 29, 2025, Sangamo Therapeutics, Inc. received an extension from Nasdaq until April 27, 2026, to comply with the minimum bid price requirement of $1.00 per share for its continued listing on The Nasdaq Capital Market. This extension follows a previous notice on April 30, 2025, indicating non-compliance with the requirement. The company aims to meet the requirement by the deadline, but failure to do so may result in delisting, with the option to appeal the decision.

The most recent analyst rating on (SGMO) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Sangamo Biosciences stock, see the SGMO Stock Forecast page.

Sangamo Biosciences CFO Resigns, New Officer Appointed

Sangamo Therapeutics, Inc. announced the resignation of its Chief Financial Officer, Prathyusha Duraibabu, effective October 1, 2025. She will transition to part-time employment, continuing as the principal financial officer. In response, the company appointed Nikunj Jain as the principal accounting officer, effective the same date. Jain, who has been with the company since 2021, brings extensive experience from his previous roles at Coherus Biosciences and Deloitte & Touche LLP. The company has formalized employment agreements with both Jain and Duraibabu, outlining their compensation and benefits.

The most recent analyst rating on (SGMO) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Sangamo Biosciences stock, see the SGMO Stock Forecast page.

Sangamo Biosciences CFO Resignation Announced

On September 9, 2025, Prathyusha Duraibabu announced her resignation as Chief Financial Officer of Sangamo Therapeutics, effective October 1, 2025, to join a private AI company. Her departure is amicable and unrelated to any company disagreements. She will continue part-time to ensure continuity until a successor is appointed. The company acknowledges her significant contributions, particularly in strategic collaborations and investments, which have strengthened Sangamo’s position in the genomic medicines industry.

The most recent analyst rating on (SGMO) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Sangamo Biosciences stock, see the SGMO Stock Forecast page.

Sangamo Biosciences Reveals Promising Fabry Disease Study Results

On September 4, 2025, Sangamo Therapeutics announced updated clinical data from its Phase 1/2 STAAR study of isaralgagene civaparvovec, a gene therapy for Fabry disease, presented at ICIEM2025 in Kyoto. The study showed promising results, with patients demonstrating stable cardiac function and significant improvements in disease severity and quality of life. The company is preparing a Biologics License Application for accelerated approval, targeting submission in early 2026, contingent on securing additional funding. These developments could enhance Sangamo’s position in the gene therapy market and offer new treatment options for Fabry disease patients.

The most recent analyst rating on (SGMO) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Sangamo Biosciences stock, see the SGMO Stock Forecast page.